£14 million to kick-start broad biotech collaboration in oncology

18 September 2018
2019_biotech_test_vial_discovery_big

A £14 million ($18 million) investment from Cancer Research UK will go towards the establishment of a new research center for biopharmaceuticals, based in London.

The new Cancer Research UK City of London Centre will act as a hub for researchers from leading research centers, including University College London (UCL), King’s College London, Queen Mary University of London and the Francis Crick Institute.

Research will span all cancer types, with a focus on childhood cancers. The center will be driven by an ethos of collaboration and training.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology